Human African trypanosomiasis, chemotherapy and CNS disease

Rodgers, J. (2009) Human African trypanosomiasis, chemotherapy and CNS disease. Journal of Neuroimmunology, 211(1-2), pp. 16-22. (doi: 10.1016/j.jneuroim.2009.02.007)

Full text not currently available from Enlighten.

Publisher's URL:


Trypanosomes have been recognised as human pathogens for over a century. Human African trypanosomiasis is endemic in an area sustaining 60 million people and is fatal without chemotherapeutic intervention. Available trypanocidal drugs require parenteral administration and are associated with adverse reactions including the development of a severe post-treatment reactive encephalopathy (PTRE). Following infection the parasites proliferate in the systemic compartment before invading the CNS where a cascade of events results in neuroinflammation. This review summarises the clinical manifestations of the infection and chemotherapeutic regimens as well as the current research findings and hypotheses regarding the neuropathogenesis of the disease.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Rodgers, Dr Jean
Authors: Rodgers, J.
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Journal of Neuroimmunology
Publisher:Elsevier BV
ISSN (Online):1872-8421
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
443321Combination chemotherapy of human African trypanosomiasis - the potential of drug synergism and the blood-brain barrierPeter KennedyMedical Research Council (MRC)G0601059Institute of Infection Immunity and Inflammation